bloedvataandoeningen, arteriosclerose Conn's syndrome primary hyperaldosteronism
Conditions
Interventions
hyperaldosteronism
inflammation
innate immune system
PET scan
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Patients with PA (primary hyperaldosteronism): - Diagnosis of PA according to current guideline - Age >=18 yrs - Written informed consent;Patients with essential hypertension: - Exclusion of PA according to current guidelines - Age >=18 yrs - Written informed consent
Exclusion criteria
Exclusion criteria: - Treatment with MR antagonists within the 4 weeks before participation - Smoking - Diabetes mellitus - Previous cardiovascular events (stroke, TIA, myocardial infarction) - Heart failure - Auto-inflammatory or auto-immune diseases - Use of immunomodulating drugs - Renal failure (MDRD 35 - Previous vaccination within 3 months prior to study entry. - Current infection or clinically significant infections within 3 months before participation (defined as fever >38.5).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study parameter/endpoint: Vascular wall inflammation in the aorta, the left and right carotid artery and the left and right iliac and femoral arteries, as detected with FDG-PET scanning, according to current European guidelines. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters/endpoints: The inflammatory/atherogenic phenotype of circulating monocytes in PA patients. FDG uptake in spleen and bone marrow. | — |
Countries
The Netherlands
Outcome results
None listed